IFM Investors Pty Ltd Raises Stock Position in Amgen Inc. $AMGN

IFM Investors Pty Ltd increased its position in shares of Amgen Inc. (NASDAQ:AMGN) by 2.9% during the first quarter, HoldingsChannel.com reports. The fund owned 109,804 shares of the medical research company’s stock after acquiring an additional 3,051 shares during the period. IFM Investors Pty Ltd’s holdings in Amgen were worth $38,635,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also bought and sold shares of the company. Robeco Institutional Asset Management B.V. increased its stake in Amgen by 10.0% in the fourth quarter. Robeco Institutional Asset Management B.V. now owns 481,453 shares of the medical research company’s stock valued at $157,584,000 after acquiring an additional 43,884 shares during the last quarter. Curtis Advisory Group LLC purchased a new stake in Amgen during the fourth quarter valued at about $1,669,000. Adell Harriman & Carpenter Inc. lifted its stake in Amgen by 7.9% during the fourth quarter. Adell Harriman & Carpenter Inc. now owns 22,008 shares of the medical research company’s stock worth $7,204,000 after purchasing an additional 1,609 shares during the last quarter. Fideuram Intesa Sanpaolo Private Banking S.P.A. bought a new stake in Amgen during the fourth quarter worth about $22,441,000. Finally, Robinhood Asset Management LLC purchased a new position in shares of Amgen in the 4th quarter worth about $17,526,000. 76.50% of the stock is currently owned by hedge funds and other institutional investors.

More Amgen News

Here are the key news stories impacting Amgen this week:

• Positive Sentiment: Amgen remains one of the most watched stocks on Zacks, and recent commentary notes the shares have had a strong multi-week and year-to-date run, suggesting continued investor interest and momentum. Article Title
• Neutral Sentiment: Viridian Therapeutics’ new FDA approval for Lumvoa is being viewed as a stronger competitor in thyroid eye disease, adding competitive pressure to Amgen’s Tepezza franchise rather than changing Amgen’s fundamentals directly. Article Title
• Negative Sentiment: The European Medicines Agency’s CHMP recommended revoking Tavneos’ marketing authorization in the EU, which raises the risk of lost international sales and creates a fresh regulatory overhang for Amgen. Article Title
• Negative Sentiment: The New England Journal of Medicine retracted the trial paper that supported Tavneos after FDA-related findings, increasing concerns about the reliability of the clinical data behind a drug that generated substantial revenue for Amgen. Article Title

Insiders Place Their Bets

In other news, SVP Nancy A. Grygiel sold 1,237 shares of the stock in a transaction that occurred on Monday, May 4th. The stock was sold at an average price of $323.73, for a total transaction of $400,454.01. Following the completion of the sale, the senior vice president owned 7,009 shares of the company’s stock, valued at approximately $2,269,023.57. This represents a 15.00% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Insiders own 0.85% of the company’s stock.

Amgen Stock Up 0.4%

AMGN opened at $362.12 on Wednesday. Amgen Inc. has a 12 month low of $269.77 and a 12 month high of $391.29. The company has a current ratio of 1.26, a quick ratio of 1.01 and a debt-to-equity ratio of 5.65. The business’s 50-day moving average price is $341.06 and its 200-day moving average price is $347.04. The company has a market cap of $195.44 billion, a P/E ratio of 25.20, a P/E/G ratio of 3.62 and a beta of 0.42.

Amgen (NASDAQ:AMGN) last issued its earnings results on Thursday, April 30th. The medical research company reported $5.15 earnings per share for the quarter, beating the consensus estimate of $4.77 by $0.38. Amgen had a return on equity of 137.41% and a net margin of 20.96%.The company had revenue of $8.62 billion during the quarter, compared to analysts’ expectations of $8.58 billion. During the same period in the prior year, the business posted $4.90 EPS. Amgen’s quarterly revenue was up 5.8% compared to the same quarter last year. Amgen has set its FY 2026 guidance at 21.700-23.100 EPS. On average, equities analysts expect that Amgen Inc. will post 22.39 EPS for the current year.

Analyst Ratings Changes

Several equities analysts have recently commented on the company. Guggenheim reduced their price objective on Amgen from $351.00 to $340.00 and set a “neutral” rating on the stock in a research report on Monday, May 4th. Royal Bank Of Canada reaffirmed a “positive” rating on shares of Amgen in a research note on Thursday, June 18th. Erste Group Bank reiterated a “hold” rating on shares of Amgen in a research report on Tuesday, May 5th. Weiss Ratings reissued a “buy (b)” rating on shares of Amgen in a research note on Thursday, June 18th. Finally, Piper Sandler restated an “overweight” rating on shares of Amgen in a report on Friday, June 12th. Two research analysts have rated the stock with a Strong Buy rating, eleven have given a Buy rating, fifteen have issued a Hold rating and two have assigned a Sell rating to the company. According to MarketBeat, the company presently has a consensus rating of “Hold” and an average price target of $354.42.

Amgen Profile

Amgen Inc (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen’s work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen’s commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.